Partial-accelerated irradiation with stereotactic radiotherapy at a dose of 30 Gy in 5 fractions in early breast cancer

Partial-accelerated irradiation with stereotactic radiotherapy at a dose of 30 Gy in 5 fractions in early breast cancer

Purpose To evaluate feasibility of accelerated partial breast irradiation (APBI) using stereotactic radiotherapy (SBRT) Thirty Gy delivered in 5 fractions for patients with early breast cancer. Methods Between January 1st, 2018, and December 31s, 2022, we conducted 117 treatments for patients with e...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology Vol. 26; no. 8; pp. 1872 - 1877
Main Authors: Albendea Roch, Javier, Anchuelo Latorre, Javier T., Galdós Barroso, M. Piedad, Navarrete Solano, P., Rivero Pérez, Ana Laura, Pinto Guevara, Frandeina, García Lamela, Mara, Olloqui Urroz, Javier, Díaz de Tuesta, M., Mazaira, Jesús, Muñoz, Pedro, Prada Gómez, Pedro J.
Format: Journal Article
Language:English
Published: Cham Springer International Publishing 01-08-2024
Subjects:
Adult
Aged
Aged, 80 and over
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Carcinoma, Ductal, Breast - mortality
Carcinoma, Ductal, Breast - pathology
Carcinoma, Ductal, Breast - radiotherapy
Carcinoma, Ductal, Breast - surgery
Dose Fractionation, Radiation
Feasibility Studies
Female
Follow-Up Studies
Humans
Mastectomy, Segmental
Medicine
Medicine & Public Health
Middle Aged
Oncology
Radiosurgery - adverse effects
Radiosurgery - methods
Research Article
Retrospective Studies
Breast
Radiotherapy
Stereotactic
Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate feasibility of accelerated partial breast irradiation (APBI) using stereotactic radiotherapy (SBRT) Thirty Gy delivered in 5 fractions for patients with early breast cancer. Methods Between January 1st, 2018, and December 31s, 2022, we conducted 117 treatments for patients with early-stage breast cancer. All patients underwent conservative surgery followed by APBI using stereotactic external beam radiotherapy. We analyzed local, regional, distant control, overall survival, toxicity, and cosmetic outcomes. Results The average age was 62 years. 21.3% ductal and 78.7% invasive carcinomas. Regarding the PTV volume, the median was 198.8 cc (38–794 cc). Treatments were completed in all cases. The median follow-up period was of 21 months (1–62 months). Regarding acute toxicity, no Grade 3–4 toxicities were recorded. One patient experienced Grade 2 neuropathic pain. One patient developed subacute fibrosis and two patients developed telangiectasia as subacute and chronic toxicity. Cosmetic results were “good” or “very good” in 96.3% of cases. None of the patients relapsed at any level (local, regional, or distant) and overall survival during follow.up was 100%. Conclusion APBI with SBRT 30 Gy in 5 fractions in early-stage breast cancer is a feasible technique, very-well tolerated and has excellent oncologic and cosmetic outcome during our follow-up period.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1699-3055
1699-3055
DOI:10.1007/s12094-024-03405-8